Larry Dillaha, M.D. is an experienced executive with 20 years of experience in the pharmaceutical industry. Prior to joining Melt Pharmaceuticals as Chief Executive Officer in June 2021, he served as the Chief Medical Officer of Harrow Health, where he managed the clinical development of all Harrow drug candidates throughout its portfolio of businesses. Previously, he served as Chief Executive Officer of both Repros Therapeutics and CavtheRx, an inception stage biotechnology company, as well as Chief Operating Officer and Chief Medical Officer for other specialty pharmaceutical companies. Dr. Dillaha has served as the senior leader on numerous FDA-approved 505(b)(2) development programs across a broad range of therapeutic areas, generating more than $1 billion in revenues. Dr. Dillaha earned an M.D. degree from the University of Tennessee, Memphis.

Mark L. Baum, J.D., a founder of Melt Pharmaceuticals, is the founder and CEO of Harrow, a commercial stage pharmaceutical company focused on providing patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets. Mr. Baum is also a founder and former board member of Eton Pharmaceuticals and a founder and current board member of Surface Pharmaceuticals. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Prior to Harrow, as the founder of TBLF, LLC, a private investment fund, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on leading national media outlets. He holds a Bachelors in Political Science and Philosophy from the University of Texas at Arlington and a Juris Doctor from California Western School of Law.  

John Berdahl, M.D., is a board-certified ophthalmologist and one of the co-inventors of the Melt technology. He is also a founder, board member and Chief Medical Officer of Equinox Ophthalmic, Inc. (“Equinox”), which is developing a unique way to lower eye pressure for glaucoma treatment. He has performed more than 25,000 eye surgeries and his practice has experience using the MKO Melt in over 10,000 surgeries. He has been involved in 37 FDA-monitored clinical trials in ophthalmology. He is one of the few surgeons in the United States who is fellowship trained in cornea, glaucoma, and refractive surgery. Dr. Berdahl created astigmatismfix.com, which helps thousands of surgeons per month fix residual astigmatism after cataract surgery. In an effort to improve access to care, he co-founded ExpertOpinion.MD. Dr. Berdahl also serves as Medical Director of Dakota Lions Sight & Health, an eye and tissue donation nonprofit, and as an Ophthalmologist with Vance Thompson Vision. In addition to over 45 peer-reviewed articles, over 35 book chapters, hundreds of presentations at national and international meetings, Dr. Berdahl is also highly regarded by his peers consistently being named as an influential and top ophthalmologist in the field. Dr. Berdahl holds a Bachelors in Physics from Augustana College and a Doctor of Medicine from Mayo Medical School.

J. Andy Corley is an established leader and entrepreneur in the eye-care industry. Notably, he introduced private pay procedures to the eye-care space, which have had a prominent role in the growth of ophthalmology. Mr. Corley co-founded Eyeonics, Inc. in 1998 to develop and market the crystalens intraocular lens for the treatment of cataracts. As CEO, he worked to invent and pioneer the “premium channel” for cataract surgery–creating over $10 billion in value for the industry and granting patients choice and control on upgraded healthcare decisions. Eyeonics was sold to Bausch and Lomb, where Mr. Corley served as President of the surgical division until forming Yelroc Consulting. Mr. Corley also co-founded Flying-L Partners, which invests in and develops innovative technology in the ophthalmic sector. He is currently Chairman of the board of directors of RxSight, Inc. (Nasdaq: RXST), a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery, and Neurolens, a prescription lenses company focusing on linking optometry and neurology. He is also a member of the board of Equinox and a member of the board of the Loving Eyes Foundation. He holds a Bachelor of Business Administration in Management from Georgia Southern University.

Arthur Laffer, Ph.D., is a renowned economist and the founder and Chief Economist of Laffer Associates, an economic research and consulting firm. Dr. Laffer served as Chairman of Laffer Investments, a registered investment advisor, from 1999 until 2019. Dr. Laffer has extensive experience public company board experience, and serves as a director of NexPoint Real Estate Finance, Inc. (NYSE: NREF), a commercial mortgage real estate investment trust, NexPoint Residential Trust, Inc. (NYSE: NXRT), a real estate investment trust focused on well-located, middle-income, multifamily properties in large cities, primarily in the southeastern and southwestern U.S., and VerifyMe, Inc. (Nasdaq: VRME), a technology solutions provider specializing in products to connect brands with consumers. Dr. Laffer has also served as Secretary of the 1065 Institute, Inc., a Nashville-based nonprofit focused on supply-side economic research, since August 2016. Dr. Laffer holds a Bachelor of Arts in Economics from Yale University, an M.B.A. in Economics from Stanford University and a Doctorate in Economics from Stanford University. Dr. Laffer has decades of experience providing economic advice to businesses, individuals, and governments, and is widely recognized for his thought leadership and contributions to the field of economics.